药物分子形式 生物制剂(Biologics) 小分子(SMOL) 偶联药物(XDC)||基因药物(genetic medicine) 小核酸药物(siRNA) | 分子胶(molecular qlue) 其他平台技术(platform technology) 拜耳作为深度融入中国创新生态的跨国药企龙头企业, 持续加大对中国创新的关注以及资源投入,积极携手中国的 创新力量,不断探索合作创新的更多可能,旨在合力发掘并 带来中国的下一个"重磅创新"。 我们宣布即日起正式启动拜耳中国"共创·新药"大赛, 诚挚邀请中国创新者及生物技术公司提交并展示具有突破创新 潜力的研发管线、在研药物分子或新型技术,具体范围如下: 目标治疗领域 Precision Oncology 精准实体肿瘤治疗 Precision Cardiorenal Diseases 精准心肾疾病治疗 Immunology & Inflammation 免疫学及炎症 研发管线阶段 从早期临床前候选化合物(pre-PCC) 到临床概念验证 (clinical PoC) 参选项目将经过拜耳中国及全球研发与BD专家组成的 评审委员会从创新水平、关键数据、推进速度以 ...

本次交易完成后，苑东生物间接持有上海超阳的股权比例将由11.3636%增加至30.6818%，上海超阳将 成为苑东生物施加重大影响的参股公司。 苑东生物表示，上海超阳拥有专业的创新药研发技术和团队，本次受让上海超阳股权是基于看好上海超 阳创新药管线及创新药团队的发展，符合公司战略发展规划，有利于加快推进公司创新转型战略的实施 步伐。 苑东生物同时提示风险，上海超阳是一家致力于创新药研发的生物科技公司，创新药具有投入大、周期 长、收益高、风险大的特点，投资回报周期长，未来可能面临宏观经济环境、医药行业发展及相关产业 苑东生物(688513)6月26日晚公告，公司全资子公司苑东生物投资管理（上海）有限公司（简称"上海投 资公司"）作为投资主体拟受让上海超阳原股东吴汉超、北京齐力佳科技有限公司（简称"齐力佳"）持 有的部分股权，其中，拟以810万元受让吴汉超所持有的上海超阳7.9545%的股权，对应上海超阳注册 资本700万元；拟以1158万元受让齐力佳所持有的上海超阳11.3636%的股权，对应上海超阳注册资本 1000万元，资金来源均为自有资金。 政策、市场需求变化、企业经营管理等多方面因素的影响，因此，上海超 ...

基金"专业买手"别出心裁 一键"打包"ETF渐成新风尚 随着ETF产品供给日益丰富，投资者如何根据自身的投资需求选择合适的ETF产品，成为行业亟待解决 的问题。今年以来，包括中欧基金、平安基金、兴证全球基金、上银基金等在内的多家公募机构纷纷上 报ETF-FOF产品，试图探索以FOF组合思路解决这一问题。被誉为基金"专业买手"的FOF，在居民财富 配置中具有重要作用。相比传统的FOF产品，记者从业内人士处了解到，ETF-FOF产品的优势主要体现 在资金使用效率较高、费率相对较低、能够跟其它普通基金一样"T+1"披露估值。不过面对市场上纷繁 复杂的ETF产品，ETF-FOF策略对于公募机构投研团队的宏观经济研究、市场分析、资产配置能力都提 出了更高的要求，"定量+定性"结合或有助于科学化的资产配置。（中国证券报） 中国证监会：交易所债券市场科创债达1.2万亿元 在国务院新闻办公室22日举行的新闻发布会上，中国证监会首席风险官、监管发行司司长严伯进介绍， 近年来证监会以科创板、创业板一系列的改革为契机，推动创新链、产业链、金融链等，加快深度融 合。中国证监会首席风险官监管发行司司长严伯进：新上市公司的科技含量在不断 ...

Core Viewpoint - Cancer remains a significant challenge in modern society, with a new revolutionary technology, targeted protein degradation, offering potential solutions for previously "undruggable" targets [1][2]. Group 1: Targeted Protein Degradation Technology - PROTAC (Proteolysis Targeting Chimeras) is an emerging therapeutic strategy that targets and degrades proteins associated with cancer and other diseases, with approximately 3,000 proteins linked to these conditions, but only about 700 are currently druggable [2][3]. - PROTAC operates by briefly binding to the target protein and directing it to the cell's natural degradation system, allowing for efficient and sustained effects with minimal dosage [2][3]. - The mechanism of PROTAC is described as "capture-release," which allows for the complete elimination of pathogenic proteins, addressing multiple disease-causing pathways [2]. Group 2: Clinical Trials and Developments - Since 2019, at least 30 PROTACs have entered clinical trials, primarily targeting cancer, with three PROTACs currently in Phase III trials for breast cancer, prostate cancer, and leukemia [3][4]. - The first PROTAC to enter Phase III trials is vepdegestrant, developed by Arvinas and Pfizer, which has shown to extend disease-free survival in patients with a specific breast cancer mutation compared to standard anti-estrogen therapies [3]. - Other PROTACs in Phase III trials target the androgen receptor in metastatic prostate cancer and the BTK enzyme in chronic lymphocytic leukemia, addressing issues of drug resistance in advanced cancers [3]. Group 3: Limitations and Future Prospects - Despite the promising potential of PROTACs, they face limitations, such as difficulty in targeting membrane-embedded proteins and the risk of unintended degradation of other proteins [4]. - The first approval of a PROTAC is anticipated to be a significant milestone, likely targeting an already druggable cancer-related protein, while true breakthroughs would involve previously untargeted proteins [4]. - Molecular glue is emerging as another potential protein degradation agent, which operates differently from PROTAC by altering the surface of ubiquitin ligases to facilitate protein degradation without direct binding [5].